Virtus Biotech ETF
18 hedge funds and large institutions have $13.1M invested in Virtus Biotech ETF in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 2 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
25% more capital invested
Capital invested by funds: $10.4M → $13.1M (+$2.63M)
8.78% more ownership
Funds ownership: 25.14% → 33.92% (+8.8%)
6% more funds holding
Funds holding: 17 → 18 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$517K |
| 2 |
VF
Virtu Financial
New York
|
+$192K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$115K |
| 4 |
LPL Financial
San Diego,
California
|
+$65K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$61.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$398K |
| 2 |
Jane Street
New York
|
-$259K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$8.98K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
-$1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$559 |
BBP Hedge Fund Activity: Q4 2017 in Review
18 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q4 2017, worth a combined $13.1M — up 25% from $10.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BBP positions and 2 closed out — a net gain of 1 holder — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $517K. The largest seller was Private Advisor Group, exiting entirely with an estimated $398K sold.
- 18 institutional investors held Virtus Biotech ETF (BBP) as of Q4 2017, up from 17 in Q3 2017.
- Funds reported $13.1M of Virtus Biotech ETF stock for Q4 2017, up 25% quarter-over-quarter.
- 3 funds opened new Virtus Biotech ETF positions in Q4 2017 and 2 closed out, a net change of +1 holder.
- The largest Virtus Biotech ETF buyer in Q4 2017 was Royal Bank of Canada, an estimated $517K added.
- The largest Virtus Biotech ETF seller in Q4 2017 was Private Advisor Group, an estimated $398K sold.
Based on aggregated 13F filings for Q4 2017.